# PT-141 for Men: Erectile Research and Off-Label Use > PT-141 for men is off-label and investigational. The early erectile research, the discontinued nasal route, the sildenafil-non-responder data, and the 2024 PDE-5-combination trial, cited. PT-141 was first studied in men with erectile dysfunction. None of that use is approved. Here is the early-phase record, the route that was abandoned, and the combination program now in Phase 2. ## In plain English PT-141 for men is not an approved use — read that first. The drug was originally tested in men with erectile difficulty, and in those early studies it did produce erections, sometimes even in men whom standard pills had failed. But it was never approved for men. The approval, in 2019, covers premenopausal women with low sexual desire and nothing else. Today the company is testing it in men again, this time paired with a standard erectile-dysfunction pill, but that work is still in mid-stage trials. Everything below is research, not a treatment. ## Where the male research started PT-141's first human signals were in men. As a melanocortin agonist acting centrally, systemic administration produced rapid, dose-dependent erectile activity in men with erectile dysfunction, alongside the rat and nonhuman-primate data showing erections and hypothalamic neuronal activation [1]. The mechanism was the draw: a drug that acts on the brain's sexual-motivation circuitry rather than on penile blood flow [1]. This is the off-label foundation. The compound that would later be approved for women in 2019 began as an erectile-dysfunction candidate in men — and the male/erectile evidence has remained early-phase and investigational ever since [6]. ## Does PT-141 nasal spray work? Early intranasal research in men is where the dosing thresholds came from. A double-blind, placebo-controlled study in healthy males and mild-to-moderate ED patients found dose-dependent pharmacokinetics, a median Tmax of 0.50 h (about 30 minutes to peak), and a terminal half-life of 1.85-2.09 h; a statistically significant erectile response versus placebo appeared at doses above 7 mg, with first erection at roughly 30 minutes [7]. The intranasal route was later discontinued for pharmacokinetic variability, and development moved to subcutaneous delivery [6][8]. The approved product is a subcutaneous injection, not a spray. ## How is PT-141 different from PDE-5 inhibitors? PT-141 and PDE-5 inhibitors work in entirely different places. PT-141 acts centrally, on MC4R neural circuits of sexual motivation in the brain [1]. PDE-5 inhibitors act peripherally, on vascular smooth muscle, to improve erectile blood flow. One starts in the head; the other works at the tissue. The distinction is not academic — it is why the two have been studied together. Early work co-administered low-dose intranasal PT-141 with sildenafil and reported an enhanced erectile response from combining a central agonist with a peripheral inhibitor [9]. The [PDE-5 inhibitor combination research](/pt-141-for-men) is the throughline from those first studies to the current program. ## Why PT-141 is being studied with a PDE-5 inhibitor The logic is mechanistic complementarity: a central melanocortin agonist plus a peripheral PDE-5 inhibitor cover two different links in the same chain. That idea traces back to the 2005 combination study and the subcutaneous dose-ranging work in sildenafil non-responders [8][9]. In June 2024, the drug's developer announced initiation of a Phase 2 study (~50 patients) of bremelanotide co-administered with a PDE-5 inhibitor for erectile dysfunction in PDE-5-inhibitor non-responders, with a co-formulation IND and a possible Phase 3 to follow [14]. That announcement is a corporate press release describing development status, not a peer-reviewed result. A 2008 randomized trial separately reported that intranasal bremelanotide 10 mg produced positive results in 33.5% of sildenafil non-responders versus 8.5% on placebo — but a 2023 Expression of Concern was issued for that study, so its findings should be treated as disputed [11]. We cite it only with that caveat disclosed. ## What the male/erectile record adds up to Stacked end to end: a clear central mechanism [1], dose-dependent erectile activity in early human studies [1][7], a discontinued nasal route that established a ~7 mg threshold [7], subcutaneous dose-ranging in sildenafil non-responders [8], a foundational PT-141-plus-sildenafil combination result [9], a disputed 2008 salvage study now under an Expression of Concern [11], and a live 2024 Phase 2 combination program [14]. It is a coherent, decades-long research thread — and it remains exactly that: research. No part of it is an approved use of PT-141 in men, and the male/erectile evidence is investigational, not established. --- The PT-141 (bremelanotide) record printed at billboard scale — the approved-for-women-only indication, the off-label male research, and the nausea-led tolerability set out in plain sight and cited to source; a poster of the evidence, with no clinic behind it and nothing here dispensed or sold.